← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	915	+42	+5%	$43.6B
2	2 Danaher DHR $158B	897	+7	+0.8%	$40.7B
3	3 Novartis NVS $279B	831	+15	+2%	$20.2B
4	4 Agilent Technologies A $49.1B	584	+1	+0.2%	$15.6B
5	5 Regeneron Pharmaceuticals REGN $80.1B	453	+15	+3%	$22.1B
6	6 Illumina ILMN $41B	433	+48	+12%	$22B
7	7 Revvity RVTY $17B	322	+11	+4%	$4.66B
8	8 Myriad Genetics MYGN $397M	281	+10	+4%	$3.74B
9	9 Charles River Laboratories CRL $14.4B	258	+19	+8%	$2.9B
10	10 Ionis Pharmaceuticals IONS $7.1B	234	+21	+10%	$4.53B
11	11 Alnylam Pharmaceuticals ALNY $30B	198	+29	+17%	$3.74B
12	12 Bruker BRKR $8.47B	184	+19	+12%	$2.59B
13	13 DELISTED SANGAMO THERAPEUTICS INC SGMO	145	+30	+26%	$870M
14	14 Azenta AZTA $1.63B	136	-3	-2%	$676M
15	15 Sarepta Therapeutics SRPT $1.78B	114	+6	+6%	$639M
16	16 Standard BioTools LAB $248M	107	+7	+7%	$1.15B
17	17 Arrowhead Research ARWR $8.25B	102	+35	+52%	$638M
18	18 Precigen PGEN $2.64B	100	+22	+28%	$2.2B
19	19 Pacific Biosciences PACB $619M	88	+8	+10%	$206M
20	20 DELISTED bluebird bio BLUE	83	+2	+2%	$412M
21	21 Ultragenyx Pharmaceutical RARE $1.47B	77	+77	–	$815M
22	ISEE 22 DELISTED IVERIC bio, Inc. Common Stock ISEE	73	+9	+14%	$768M
23	23 Invesco Biotechnology & Genome ETF PBE $421M	73	+13	+22%	$129M
24	24 PTC Therapeutics PTCT $4.98B	65	+4	+7%	$600M
25	NSTG 25 DELISTED NanoString Technologies, Inc. NSTG	62	+34	+121%	$240M